Sign In
Buy PFE
$25.36
-0.200 (-0.783%)
At Close: Jun 03, 2026
Baltimore Washington Financial Advisors Inc. Invests $368,000 in Pfizer Inc. $PFE
03:52am, Thursday, 27'th Nov 2025
Baltimore Washington Financial Advisors Inc. acquired a new stake in Pfizer Inc. (NYSE: PFE) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Com
Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings
12:30pm, Wednesday, 26'th Nov 2025
Valneva SE (NASDAQ: VALN) shared final immunogenicity and safety data on Wednesday from the Phase 2 study, VLA15-221, of the Lyme disease vaccine candidate, VLA15.
AbbVie and Pfizer: A Closer Look at Two Pharma Heavyweights
11:45am, Wednesday, 26'th Nov 2025
ABBV's surging immunology sales and smoother LOE path stand out as both drugmakers face a pivotal 2026.
Medicare Announces Price Cuts For 15 Drugs— Novo Nordisk's Wegovy And Ozempic To Cost $274 A Month
05:11am, Wednesday, 26'th Nov 2025
The U.S. Centers for Medicare and Medicaid Services (CMS) on Tuesday announced that it has secured lower prices for 15 of its highest‑cost medications.
Did Pfizer Just Say "Checkmate" to Novo Nordisk?
04:15am, Wednesday, 26'th Nov 2025
Pfizer has been trying to get in on the billion-dollar weight loss drug market. Novo Nordisk initially dominated this market but has been losing ground to Eli Lilly.
Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate
01:00am, Wednesday, 26'th Nov 2025
Saint-Herblain (France), November 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive final immunogenicity and safety data from Phase 2 study, VLA15-221, of Lyme dis
Is This the Best Value Stock to Buy While Markets Are Volatile?
06:24am, Tuesday, 25'th Nov 2025
Pfizer possesses several qualities that make it attractive when market volatility is high. The stock has a low forward earnings multiple and a higher -- yet still attractive -- EV-to-EBITDA ratio.
Want Over $7,000 in Annual Dividends? Invest $25,000 in Each of These 4 Stocks.
05:30am, Tuesday, 25'th Nov 2025
Income investors have been forced to seek yield in new places as stocks bump up against all-time highs. This diversified basket of blue chip names currently delivers over 7% annual yield.
JNJ Stock vs. PFE Stock: Which Pharmaceutical Giant Is A Better Buy?
05:20am, Tuesday, 25'th Nov 2025
The pharmaceutical powerhouse Johnson & Johnson (NYSE: JNJ) has significantly outperformed its competitor Pfizer (NYSE: PFE) this year. JNJ's stock has risen by almost 45%, whereas PFE has declined by
AXQ Capital LP Buys Shares of 12,829 Pfizer Inc. $PFE
04:36am, Tuesday, 25'th Nov 2025
AXQ Capital LP purchased a new position in Pfizer Inc. (NYSE: PFE) during the undefined quarter, according to its most recent 13F filing with the SEC. The firm purchased 12,829 shares of the biopharma
First-Ever Human H5N5 Case Turns Fatal In Washington State
01:07pm, Saturday, 22'nd Nov 2025
Washington reports world's first fatal human H5N5 bird flu case; officials say risk to public remains low, monitoring continues closely.
2 Healthcare Stocks for Beginner Investors With a 20-Year Time Horizon
09:20am, Saturday, 22'nd Nov 2025
If you want to invest in top healthcare stocks, both of these are worth consideration. Pfizer is moving past the pandemic era, and tremendous growth could be ahead.
U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer
01:24pm, Friday, 21'st Nov 2025
NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the U.S. Food and Drug Administra
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
10:01am, Friday, 21'st Nov 2025
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms
08:46am, Friday, 21'st Nov 2025
Pfizer's new and acquired drugs lift non-COVID revenue, with recent launches and Seagen products driving momentum into 2026 despite looming LOEs.
